Saturday , September 22 2018
Home / Letter From The Editor / Letter from the Editor #735

Letter from the Editor #735

Jun 27, 2014

It is interesting to listen to PCP’s and other prescribers talk about their reluctance to use GLP-1 analogs in their practice. This class of drugs had a great presence at this year’s ADA Scientific Sessions and many of the posters and presentations were focused on the practical use of these for our patients. Earlier this month we had a sneak preview of some of these studies and next week we are going to share another special edition on newer research. I have decided to wet your appetite for more by sharing a couple of items ahead of time. The first looks at the potential for using liraglutide with insulin and how well that works, and the second one examines the value of using dulaglutide instead of metformin in certain patients.

Our physical activity guru, Dr. Sheri Colberg, was not at the ADA due to her middle son’s graduation but that did not stop her from preparing a great feature on how activities like Tai Chi, Yoga and Active Video Games can benefit our patients. And our Advisory Board member, Dr. Aaron Vinik had some interesting things to say about the anti-DPN drug, Tapentadol-ER which we thought were important enough to share with you. 


From "dLife heads to Capitol Hill to visit the JDRF Children’s Congress, and to see what progress diabetes advocates are making in Washington. Plus, Jim Turner asks: ‘What’s the most insensitive thing someone has said about your diabetes?’" Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at

We can make a difference!

Dave Joffe, Editor-in-chief